上海市肿瘤研究所成立于1958年，1980年被确认为世界卫生组织癌症预防与控制合作中心。1985年获批筹建癌基因与相关基因国家重点实验室，1987年通过验收并对外开放。1996年与上海市科委共建基因治疗研究中试上海基地。2003年原上海市卫生局与欧洲杯竞猜平台共建欧洲杯竞猜平台肿瘤研究所。2010年，与仁济医院实现院所合一。2019年整建制划归上海市教育委员会，由欧洲杯竞猜平台和附属仁济医院共同管理。
上海市肿瘤研究所拥有实验室空间约26933平方米，分别位于三个园区，其中徐汇园区7500平方米，浦东园区新科研楼16433平方米，闵行园区欧洲杯竞猜平台闵行校区3000平方米。作为癌基因与相关基因国家重点实验室依托单位，研究所设肿瘤微环境、肿瘤分子病理研究组等20个研究组（室）和动物实验中心、科学研究公共平台、《肿瘤》杂志编辑部等辅助部门。现有在编职工138人，具有研究生学历107人，科研人员115人，其中博士79人，占68.7%。包括中国工程院院士1人、国家终身教授1人。高级职称专业技术人员33人，研究生导师29人（博导20人、硕导9人），在读研究生66人（博士生35人、硕士生31人）。
研究所致力实施“人才强所”战略，先后从国外引入国家特聘专家等一批高水平人才。十三五以来，有35人次先后入选上海领军人才、上海市优秀学科带头人、上海市科技启明星计划、上海青年科技英才扬帆计划、上海市青年拔尖人才开发计划、上海市人才发展资金等人才计划。承担各类纵向科研课题177项（国家级项目59项），科研经费达到6545.2万元。其中，科技部重大专项课题4项，国家重点研发计划2项，NSFC项目52项。研制成功全球首个肝癌CAR-T细胞，临床试验疗效显著，在国际实体瘤CAR-T免疫治疗研究领域处于领先地位。CAR-T细胞药物获国家药监局注册临床研究许可3项、美国FDA及加拿大卫生部临床试验许可各1项，在中国、美国等国家和地区同步开展临床试验研究。以第一单位获得各类科技成果奖励3项，在Nature、Gastroenterology、Gut等杂志发表SCI 论文210篇。授权发明专利15项，其中1项获得转化，技术转让金额106万元，推动转化医学研究发展。
研究所对外交往密切，先后与美国国立卫生研究院（NIH）、美国国立癌症研究院（NCI）、耶鲁大学、匹兹堡大学、范德堡大学、荷兰癌症研究所、韩国首尔大学等20多个国家的一流科研院所建立了合作关系，聘请了多位国外著名专家和教授担任顾问，推动双方学术交流。
Shanghai Cancer Institute (SCI) was founded in 1958 and was designated as WHO Collaborating Center for Research on Cancer in 1980. In 1985, the establishment of State Key Laboratory of Oncogenes and Related Genes was approved, and the laboratory passed the evaluation and was opened in1987. In 1996, Shanghai Cancer Institute and Shanghai Municipal Commission of Science and Technology set up the Gene Therapy Research Pilot Test Base in Shanghai. In 2003, Shanghai Municipal Public Health Bureau and Shanghai Jiao Tong University (SJTU) set up SJTU Cancer Institute. In 2010, Shanghai Cancer Institute and Renji Hospital were merged into Cancer Center. Shanghai Cancer Institute has been affiliated to Shanghai Municipal Education Commission in 2019 and now the institute is managed by both Shanghai Jiao Tong University School of Medicine and Renji Hospital.
Shanghai Cancer Institute has 26,933 m2 of laboratory space, located in three campuses, including 7,500 m2 in Xuhui campus, 16,433 m2 in the new research building in Pudong campus, and 3,000 m2 in Shanghai Jiao Tong University in Minhang campus. As the host of State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute set up 20 research groups (labs) such as tumor microenvironment and tumor molecular pathology, as well as research support departments such as animal experiment center, core facilities, and editorial department of Tumor Journal. Shanghai Cancer Institute has 138 full-time employees,107 with postgraduate qualifications, 115 scientific researchers, of whom 79 are PhDs, accounting for 68.7%, including 1 CAE academicians and 1 national tenured professor. There are 33 senior professional researchers, 29 graduate student supervisors (20 doctoral supervisors and 9 master supervisors), and 66 graduate students (35 doctoral students and 31 master students).
Since the 13th Five-year Plan, Shanghai Cancer Institute has undertaken 177 scientific research projects (59 national projects) with total scientific research funds of 65.452 million yuan, including 4 National Science and Technology Major Projects of the Ministry of Science and Technology of China, 2 National Key Research and Development Projects, and 52 NSFC projects. Shanghai Cancer Institute has successfully developed the world’s first CAR-T cells for liver cancer therapy with significant clinical trial outcome, making it stay ahead of international CAR-T immunotherapy research. CAR-T cell drugs have obtained 3 clinical research licenses registered by the National Medical Products Administration (NMPA), 1 clinical trial license each from the US FDA and Health Canada, and simultaneously carry out clinical trial research in China and the US. Shanghai Cancer Institute has been awarded 3 Science & Technology Awards and published 210 SCI papers on Nature, Gastroenterology, Gut, and other journals. Shanghai Cancer Institute has obtained 15 invention patents, and 1 of them has been transferred with an amount of over 1.06 million yuan, which has achieved development of translational medicine research.
Shanghai Cancer Institute has maintained frequent exchanges with foreign countries, and has established cooperation with prestigious universities and institutes in more than 20 countries, e.g. National Institutes of Health (NIH), National Cancer Institute (NCI), Yale University, University of Pittsburgh, Vanderbilt University, The Netherlands Cancer Institute, and Seoul National University. Meanwhile, it has hired several foreign famous experts and professors as advisors to promote mutual academic exchange.
